Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients

Natalia Ruetalo; Ramona Businger; Karina Althaus; Simon Fink; Felix Ruoff; Michaela Pogoda; Angelika Iftner; Tina Ganzenmüller; Klaus Hamprecht; Bertram Flehmig; Tamam Bakchoul; Markus F. Templin; Michael Schindler

doi:10.1128/mSphere.01145-20

mSphere (Feb 2021)

Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients

Natalia Ruetalo,
Ramona Businger,
Karina Althaus,
Simon Fink,
Felix Ruoff,
Michaela Pogoda,
Angelika Iftner,
Tina Ganzenmüller,
Klaus Hamprecht,
Bertram Flehmig,
Tamam Bakchoul,
Markus F. Templin,
Michael Schindler

Affiliations

Natalia Ruetalo: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
Ramona Businger: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
Karina Althaus: Institute for Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
Simon Fink: NMI, Reutlingen, Germany
Felix Ruoff: NMI, Reutlingen, Germany
Michaela Pogoda: Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
Angelika Iftner: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
Tina Ganzenmüller: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
Klaus Hamprecht: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany
Bertram Flehmig: Mediagnost GmbH, Reutlingen, Germany
Tamam Bakchoul: Institute for Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
Markus F. Templin: NMI, Reutlingen, Germany
Michael Schindler: ORCiD; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany

DOI: https://doi.org/10.1128/mSphere.01145-20
Journal volume & issue: Vol. 6, no. 1

Abstract

Read online

There is strong interest in the nature of the neutralizing antibody response against SARS-CoV-2 in infected individuals. For vaccine development, it is especially important which antibodies confer protection against SARS-CoV-2, if there is a phenomenon called antibody-dependent enhancement (ADE) of infection, and if there is cross-protection by antibodies directed against seasonal coronaviruses.

Published in mSphere

ISSN: 2379-5042 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/msphere

About the journal